HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced the signing of a binding Letter of Intent (LOI) to purchase a 49% interest in Cohen and Associates, LLC. This clinic, founded by Dr. Rebecca Cohen, is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida.
Cohen and Associates is recognized as one of the premier Interventional Psychiatry clinics in the region, offering a full range of treatments for suicidal depression, PTSD, and other CNS disorders. These treatments include ketamine, Spravato, Transcranial Magnetic Stimulation (TMS), and medication management.
Dr. Rebecca Cohen, an Interventional Psychiatrist and Psychopharmacologist specializing in mood and anxiety disorders and a nationally recognized expert in TMS, will join the HOPE family. The potential acquisition is subject to the execution of definitive transaction documents and standard closing requirements.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.